For the fourth consecutive year, outcomes for patients receiving allogeneic transplants through the Blood and Marrow Transplant Program at Roswell Park Cancer Institute (RPCI) have been shown to be significantly better than would be expected among the patient population treated.
BUFFALO, NY — From its seminal studies in the first half of the 20th century linking tobacco use and cancer incidence to its latest findings on electronic cigarettes, Roswell Park Cancer Institute (RPCI) has been a major force in tobacco-control research
PHILADELPHIA — Treatment with the drug decitabine prior to administration of chemotherapy and a cancer vaccine yielded clinical benefit for women with recurrent ovarian cancer, suggesting that this combinatorial chemoimmunotherapy may provide a new treatment option for patients with this disease,
BUFFALO, NY — On January 20 after morning practice, five Buffalo Sabres will shave their heads in front of cancer patients and fans to show their support of people in our community who are fighting cancer.
Twenty-four physicians from Roswell Park Cancer Institute (RPCI) have been named to Castle Connolly Medical Ltd.’s 2014 America’s Top Doctors list. The list is compiled annually on the basis of recommendations from physicians. A regional Top Doctors directory appears in the January issue of Buffalo Spree magazine.
Roswell Park Cancer Institute announces two key executive appointments: Armen Gallucci, FACHE, has joined RPCI as Vice President of Business Development and Outreach, and Kerry L. Kerlin has been named Chief Information Officer.
Electronic cigarettes, when used indoors, may involuntarily expose non-users to nicotine, according to a study led by Maciej Goniewicz, PhD, PharmD, of Roswell Park Cancer Institute and published by the journal Nicotine and Tobacco Research.
Researchers at the Roswell Park Cancer Institute Center for Immunotherapy are enrolling patients in three different clinical trials of novel immunotherapy approaches for treating genitourinary cancers. One of the studies will assess how patients’ immune systems respond to targeted radiation treatments for metastatic kidney cancer. Another will evaluate how patients’ immune systems respond to targeted radiation treatments for metastatic prostate cancer, in combination with immunotherapy, and a third will focus on a new type of immunotherapy for bladder cancer.